Literature DB >> 26278144

53BP1 foci as a marker of tumor cell radiosensitivity.

E Markova, S Vasilyev, I Belyaev.   

Abstract

Predicting tumor radiosensitivity has yet to be routinely integrated into radiotherapy. We analyzed the possibility to assess radiosensitivity of tumor cells based on endogenous and radiation-induced 53BP1 foci which are molecular markers of DNA double strand breaks (DSB). In eleven tumor cell lines of different origin, radiosensitivity was assessed by surviving cell fraction following irradiation with 2 Gy (SF2). 53BP1 foci were measured at 4 and 12 h post-irradiation by confocal laser microscopy and dedicated software. The correlation of 53BP1 foci and their post-irradiation kinetics with SF2 was assessed using Spearman rank test. The SF2 correlated with both excess of radiation-induced 53BP1 foci per cell at 4 h after irradiation and decay in number of 53BP1 foci from 4 to 12 h post-irradiation. The fraction of cells with multiple endogenous 53BP1 foci also correlated with SF2 of tumor cells. We conclude that the radiosensitivity of tumor cells can be predicted by kinetics of formation and decay of 53BP1 foci after irradiation. For the first time we report that the fraction of cells with multiple endogenous 53BP1 foci can be used as a marker of tumor cell radiosensitivity.

Entities:  

Keywords:  53BP1; DNA double strand breaks; clonogenic survival; radiosensitivity.; tumor cells

Year:  2015        PMID: 26278144     DOI: 10.4149/neo_2015_092

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  8 in total

1.  53BP1 inhibits the migration and regulates the chemotherapy resistance of ovarian cancer cells.

Authors:  Shuhui Hong; Xiaoyan Li; Ying Zhao; Qifeng Yang; Beihua Kong
Journal:  Oncol Lett       Date:  2018-04-27       Impact factor: 2.967

2.  Development and characterization of a new gill cell line from the striped catfish, Pangasianodon hypophthalmus (Sauvage, 1878).

Authors:  Arjunan Sathiyanarayanan; Mukunda Goswami; Naresh Nagpure; Gireesh Babu P; Dhanjit Kumar Das
Journal:  Fish Physiol Biochem       Date:  2022-02-15       Impact factor: 2.794

3.  Correlation of Particle Traversals with Clonogenic Survival Using Cell-Fluorescent Ion Track Hybrid Detector.

Authors:  Ivana Dokic; Martin Niklas; Ferdinand Zimmermann; Andrea Mairani; Philipp Seidel; Damir Krunic; Oliver Jäkel; Jürgen Debus; Steffen Greilich; Amir Abdollahi
Journal:  Front Oncol       Date:  2015-12-07       Impact factor: 6.244

4.  Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma.

Authors:  Julian Biau; Emmanuel Chautard; Leanne De Koning; Frank Court; Bruno Pereira; Pierre Verrelle; Marie Dutreix
Journal:  Radiat Oncol       Date:  2017-07-28       Impact factor: 3.481

Review 5.  A role of the 53BP1 protein in genome protection: structural and functional characteristics of 53BP1-dependent DNA repair.

Authors:  Eva Bártová; Soňa Legartová; Miroslav Dundr; Jana Suchánková
Journal:  Aging (Albany NY)       Date:  2019-04-17       Impact factor: 5.682

6.  Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy.

Authors:  Leon Emanuel Schnöller; Valerie Albrecht; Nikko Brix; Alexander Edward Nieto; Daniel Felix Fleischmann; Maximilian Niyazi; Julia Hess; Claus Belka; Kristian Unger; Kirsten Lauber; Michael Orth
Journal:  Radiat Oncol       Date:  2022-04-19       Impact factor: 4.309

7.  DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models.

Authors:  Yanyan Jiang; Elaine Willmore; Stephen R Wedge; Anderson J Ryan
Journal:  Mol Cancer Ther       Date:  2021-06-22       Impact factor: 6.261

Review 8.  Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University.

Authors:  Takahiro Oike; Hiro Sato; Shin-Ei Noda; Takashi Nakano
Journal:  Front Oncol       Date:  2016-06-09       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.